Identify the PIK3CA mutations that matter

Oncology | Breast cancer

Identify the PIK3CA mutations that matter

Empower your oncologists with results
they can trust 

The therascreen PIK3CA RGQ PCR Kit is a clinically validated in vitro diagnostic (IVD) test to identify breast cancer patients that may be eligible for treatment with the ∝-selective PI3K-inhibitor PIQRAY (alpelisib), based on the detection of a PIK3CA mutation.
Contact an expert
Discover how QIAGEN can help you and your patients.
Get in touch

Reliably detect actionable mutations

The therascreen PIK3CA RGQ PCR Kit is a unique molecular test, based on the detection of specific PIK3CA mutations in tumor DNA isolated from either FFPE tumor tissue or plasma samples. The kit detects 11 mutations in exons 7, 9, and 20 of the PIK3CA gene (exon 7: C420R; exon 9: E542K; E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and exon 20: H1047L, H1047R, H1047Y).

Product details
Breast cancer test
The tools you need to ensure patients receive the best individualized care

Solutions for precision healthcare

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products
The therascreen PIK3CA RGQ PCR Kit is intended for in vitro diagnostic use.